Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

243 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC). Preudhomme C, et al. Among authors: delmer a. N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095. N Engl J Med. 2010. PMID: 21175313 Free article. Clinical Trial.
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Guilhot F, Rigal-Huguet F, Guilhot J, Guerci-Bresler AP, Maloisel F, Rea D, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Jourdan E, Berger M, Fouillard L, Alexis M, Legros L, Rousselot P, Delmer A, Lenain P, Escoffre Barbe M, Gyan E, Bulabois CE, Dubruille V, Joly B, Pollet B, Cony-Makhoul P, Johnson-Ansah H, Mercier M, Caillot D, Charbonnier A, Kiladjian JJ, Chapiro J, Penot A, Dorvaux V, Vaida I, Santagostino A, Roy L, Zerazhi H, Deconinck E, Maisonneuve H, Plantier I, Lebon D, Arkam Y, Cambier N, Ghomari K, Miclea JM, Glaisner S, Cayuela JM, Chomel JC, Muller M, Lhermitte L, Delord M, Preudhomme C, Etienne G, Mahon FX, Nicolini FE; France Intergroupe des Leucémies Myéloïdes Chroniques, Fi-LMC. Guilhot F, et al. Among authors: delmer a. Leukemia. 2021 Aug;35(8):2332-2345. doi: 10.1038/s41375-020-01117-w. Epub 2021 Jan 22. Leukemia. 2021. PMID: 33483613 Clinical Trial.
Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO).
Lazarian G, Munger M, Quinquenel A, Dilhuydy MS, Veronese L, Luque Paz D, Guièze R, Ledoux-Pilon A, Paillassa J, Merabet F, Vial JP, Bidet A, Waultier Rascalou A, Broseus J, Roos-Weil D, Lavaud A, Molina L, Laribi K, Hivert B, Friedrich C, Carpentier B, Ysebaert L, Van Den Neste E, Willems L, Corby A, Poulain S, Eclache V, Maubec E, Martin A, Feugier P, Delmer A, Baran-Marszak F, Leprêtre S, Cymbalista F. Lazarian G, et al. Among authors: delmer a. Am J Hematol. 2021 Sep 1;96(9):E353-E356. doi: 10.1002/ajh.26274. Epub 2021 Jul 1. Am J Hematol. 2021. PMID: 34152612 Free article. No abstract available.
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia.
Bagacean C, Letestu R, Al-Nawakil C, Brichler S, Lévy V, Sritharan N, Delmer A, Dartigeas C, Leblond V, Roos-Weil D, Tomowiak C, Merabet F, Béné MC, Clavert A, Chaoui D, Genet P, Guieze R, Laribi K, Drénou B, Willems L, Puppinck C, Legendre H, Troussard X, Malartre S, Cymbalista F, Michallet AS. Bagacean C, et al. Among authors: delmer a. Blood Adv. 2022 Jan 11;6(1):207-211. doi: 10.1182/bloodadvances.2021006215. Blood Adv. 2022. PMID: 34844264 Free PMC article.
Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA).
Manson G, Herbaux C, Schiano JM, Casasnovas O, Stamatoullas A, Deau B, Schmitt A, Regny C, Bouabdallah K, Chauchet A, Ghesquieres H, Tempescul A, Dulery R, Nicolas-Virelizier E, Delmer A, Borel C, Dercle L, Brice P, Houot R; Lymphoma Study Association (LYSA). Manson G, et al. Among authors: delmer a. Br J Haematol. 2022 Jul;198(1):203-206. doi: 10.1111/bjh.18198. Epub 2022 Apr 21. Br J Haematol. 2022. PMID: 35445392 Free article. No abstract available.
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Balsat M, Alcazer V, Etienne G, Huguet F, Berger M, Cayssials E, Charbonnier A, Escoffre-Barbe M, Johnson-Ansah H, Legros L, Roy L, Delmer A, Ianotto JC, Orvain C, Larosa F, Meunier M, Amé S, Andreoli A, Cony-Makhoul P, Morisset S, Tigaud I, Rea D, Nicolini FE. Balsat M, et al. Among authors: delmer a. Leuk Res. 2023 Jul;130:107308. doi: 10.1016/j.leukres.2023.107308. Epub 2023 May 9. Leuk Res. 2023. PMID: 37230027
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
Durot E, Tomowiak C, Michallet AS, Dupuis J, Hivert B, Leprêtre S, Toussaint E, Godet S, Merabet F, Van Den Neste E, Ivanoff S, Roussel X, Zini JM, Regny C, Lemal R, Sutton L, Perrot A, Le Dû K, Kanagaratnam L, Morel P, Leblond V, Delmer A. Durot E, et al. Among authors: delmer a. Br J Haematol. 2017 Nov;179(3):439-448. doi: 10.1111/bjh.14881. Epub 2017 Aug 2. Br J Haematol. 2017. PMID: 28770576 Free article.
243 results